Addex Convenes Annual General Meeting 2023
05 May 2023 - 3:00PM
Addex Convenes Annual General Meeting 2023
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 5,
2023 - Addex Therapeutics (SIX: ADXN and
Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering
allosteric modulation-based drug discovery and development,
announced today that its Annual General Meeting will take place on
Wednesday May 31, 2023, at 11:00 am CEST at the Campus Biotech,
Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
Agenda
1. Approval of the Annual
Report, the Annual Financial Statements and the Consolidated
Financial Statements for the business year
20222. Consultative vote on the Compensation
Report for the business year 20223. Appropriation
of the results4. Discharge of the members of the
Board of Directors and of the Executive
Management5. Re-elections of the members of the
Board of Directors and re-election of the Chairman of the Board of
Directors5.1. Re-election of Vincent Lawton
as member and Chairman of the Board of
Directors5.2. Re-election of Raymond Hill as
member of the Board of
Directors5.3. Re-election of Timothy Dyer as
member of the Board of
Directors5.4. Re-election of Roger Mills as
member of the Board of
Directors5.5. Re-election of Jake Nunn as
member of the Board of
Directors5.6. Re-election of Isaac Manke as
member of the Board of Directors6. Re-elections of
the members of the Compensation
Committee6.1. Re-election of Vincent Lawton
as member of the Compensation
Committee6.2. Re-election of Raymond Hill as
member of the Compensation Committee7. Re-election
of the Auditors8. Re-election of the Independent
Voting Rights Representative9. Amendments to the
Articles of Association9.1. Introduction of
a capital band (article 3b of the Articles of
Association)9.2. Increase of the conditional
share capital and amendments related to the new corporate law
(article 3c of the Articles of
Association)9.3. Allowing loans to members
of the Board of Directors and the Executive Management (article 30
of the Articles of Association)9.4. No
renewal of the exemption from the duty to make an offer (opting-out
of mandatory offer rules)10. Approval of the
compensation of the members of the Board of Directors and of the
Executive Management10.1. Compensation of
the members of the Board of
Directors10.1.1. For the period from the
2022 AGM to 2023 AGM 10.1.2. For the period
from the 2023 AGM to 2024
AGM10.2. Compensation of the members of the
Executive management10.2.3. For the
financial year 2022
10.2.4. For the financial
year 202411. MiscellaneousThe full invitation to
the AGM 2023 may be found in the General Meetings section of the
Company’s website here.
About Addex
Therapeutics:Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the development
and commercialization of an emerging class of novel orally
available, small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional, non-allosteric molecules
and may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with
Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept
clinical trial for the treatment of epilepsy. Addex's second
clinical program, dipraglurant (mGlu5 negative allosteric modulator
or NAM), is under evaluation for future development in a range of
indications. Indivior PLC has licensed Addex’s GABAB PAM program
for the development of drug candidates, with a focus on substance
use disorder. Addex is also advancing a broad preclinical pipeline,
which includes development of a range of GABAB PAMs for CMT1A,
chronic cough and several types of pain, mGlu7 NAM for stress
related disorders, mGlu2 NAM for mild neurocognitive disorders and
depression, M4 PAM for schizophrenia and other forms of
psychosis, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are
listed on the SIX Swiss Exchange and American Depositary Shares
representing its shares are listed on the NASDAQ Capital Market,
and trade under the ticker symbol "ADXN" on each exchange.
Contacts:
Tim DyerChief
Executive OfficerTelephone: +41 22 884 15 55
PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2022, as filed with the SEC on March 30, 2023,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From May 2023 to May 2024